174 related articles for article (PubMed ID: 16098254)
61. Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients.
Fernandes GDS; Braghiroli MI; Artioli M; Paterlini ACCR; Teixeira MC; Gumz BP; Girardi DDM; Braghiroli OFM; Costa FP; Hoff PM
J Gastrointest Cancer; 2018 Dec; 49(4):470-475. PubMed ID: 28884286
[TBL] [Abstract][Full Text] [Related]
62. Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy.
Mirakhorli M; Rahman SA; Abdullah S; Vakili M; Rozafzon R; Khoshzaban A
Mol Med Rep; 2013 Feb; 7(2):613-7. PubMed ID: 23232902
[TBL] [Abstract][Full Text] [Related]
63. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK
J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875
[TBL] [Abstract][Full Text] [Related]
64. Efficacy of oxaliplatin in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):9-14. PubMed ID: 11204666
[TBL] [Abstract][Full Text] [Related]
65. Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.
Kim GP; Grothey A
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S89-97. PubMed ID: 16336754
[TBL] [Abstract][Full Text] [Related]
66. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
67. A Preliminary Report of the Relationship Between Gene Polymorphism of
Yao W; Sun Y; Sun Y; Chen P; Meng Z; Xiao M; Yang X
DNA Cell Biol; 2019 Dec; 38(12):1512-1518. PubMed ID: 31613654
[TBL] [Abstract][Full Text] [Related]
68. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
69. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924
[TBL] [Abstract][Full Text] [Related]
70. Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
Cassinello J; Escudero P; Salud A; Marcos F; Pujol E; Pérez-Carrión R; Colmenarejo A; González del Val R; Valero J; Oruezábal MJ; Guillem V; García I; Arcediano A; Marfà X
Clin Colorectal Cancer; 2003 Aug; 3(2):108-12. PubMed ID: 12952567
[TBL] [Abstract][Full Text] [Related]
71. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E
Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265
[TBL] [Abstract][Full Text] [Related]
72. Folate pathway genes linked to mitochondrial biogenesis and respiration are associated with outcome of patients with stage III colorectal cancer.
Odin E; Sondén A; Carlsson G; Gustavsson B; Wettergren Y
Tumour Biol; 2019 Jun; 41(6):1010428319846231. PubMed ID: 31223065
[TBL] [Abstract][Full Text] [Related]
73. Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer.
Wang X; Zuo D; Chen Y; Li W; Liu R; He Y; Ren L; Zhou L; Deng T; Wang X; Ying G; Ba Y
Br J Cancer; 2014 Nov; 111(10):1965-76. PubMed ID: 25321193
[TBL] [Abstract][Full Text] [Related]
74. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness.
Snoussi K; Mahfoudh W; Bouaouina N; Fekih M; Khairi H; Helal AN; Chouchane L
BMC Cancer; 2010 Jun; 10():283. PubMed ID: 20540789
[TBL] [Abstract][Full Text] [Related]
75. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.
Lurje G; Zhang W; Schultheis AM; Yang D; Groshen S; Hendifar AE; Husain H; Gordon MA; Nagashima F; Chang HM; Lenz HJ
Ann Oncol; 2008 Oct; 19(10):1734-41. PubMed ID: 18550579
[TBL] [Abstract][Full Text] [Related]
76. Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy.
Chen J; Luo X; Xie G; Chen K; Jiang H; Pan F; Li J; Ruan Z; Pang X; Liang H
Medicine (Baltimore); 2016 May; 95(19):e3652. PubMed ID: 27175691
[TBL] [Abstract][Full Text] [Related]
77. Impact of EGFR gene polymorphisms on anticancer drug cytotoxicity in vitro.
Puyo S; Le Morvan V; Robert J
Mol Diagn Ther; 2008; 12(4):225-34. PubMed ID: 18652519
[TBL] [Abstract][Full Text] [Related]
78. The expression of interleukin-8 and interleukin-8 receptors in endometrial carcinoma.
Ewington L; Taylor A; Sriraksa R; Horimoto Y; Lam EW; El-Bahrawy MA
Cytokine; 2012 Aug; 59(2):417-22. PubMed ID: 22626766
[TBL] [Abstract][Full Text] [Related]
79. R497K polymorphism in epidermal growth factor receptor gene is associated with the risk of acute coronary syndrome.
Gao LB; Zhou B; Zhang L; Wei YS; Wang YY; Liang WB; Lv ML; Pan XM; Chen YC; Rao L
BMC Med Genet; 2008 Jul; 9():74. PubMed ID: 18664296
[TBL] [Abstract][Full Text] [Related]
80. Epidermal growth factor receptor gene polymorphisms are associated with prognostic features of breast cancer.
Leite MS; Giacomin LC; Piranda DN; Festa-Vasconcellos JS; Indio-do-Brasil V; Koifman S; de Moura-Neto RS; de Carvalho MA; Vianna-Jorge R
BMC Cancer; 2014 Mar; 14():190. PubMed ID: 24629097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
